Skip to content

Oculis

US · OCS #3716 by market cap
7.06 -0.38 -5.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 7.10 -4.51%
After-hours 7.06 0.00%
29.936.837.062026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on OCS?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bearish
  • Recent price momentum is -54.8% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 2.6% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Return on equity -73.5% Better than 7%
Return on invested capital -73.2% Better than 3%
Momentum F

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -46.0% Better than 7%
6-month return -76.1% Better than 1%
12-month return (ex latest month) -58.0% Better than 1%
Distance below 52-week high 79.5% Better than 2%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 6.0x Better than 89%
Debt to assets 1.0% Better than 93%
Interest coverage -118.0x Better than 5%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 461.9% Better than 99%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -7.59%
1M -5.74%
3M -46.27%
6M -74.70%
YTD -64.65%
1Y -63.26%
3Y -26.53%
5Y -27.66%

Key statistics

Price & volume

Prev close
7.44
Open
7.38
Day range
6.98 - 7.43
Avg price
7.14
Volume
235.18K
Turnover
1.68M
Amplitude
6.12%
52-week range
6.78 - 34.48

Valuation

P/E
-3.15
P/E (TTM)
-4.42
P/B
1.77
EPS
-2.24
Net profit
-138.64M
Net assets
247.31M

Share structure

Market cap
437.15M
Float cap
371.21M
Shares out
61.92M
Float shares
52.58M

Dividend & listing

Dividend (TTM)
0.00
Listing date
--
52-week range 1% of range
6.78 34.48

79.5% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-1.77M net over the window

Short interest

Shares short
1.58M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Oculis (OCS)?

Oculis last traded at 7.06. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Oculis's market cap?

About 437.15M.

What is the P/E ratio of Oculis?

The trailing twelve-month P/E is -4.42. The Valuation tab shows it against the stock's own five-year range.

Does Oculis pay a dividend?

Oculis does not currently pay a regular dividend.

Is Oculis a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 39.67, which implies 461.9% upside from the current price. This is not investment advice.

What is Oculis's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Oculis a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Oculis discussion 0 comments

Add a comment